moneyheap
INO · Analysis updated Nov 3, 2026, 2:33 AM ET
Why is Inovio Pharmaceuticals, Inc. (INO) stock moving?
Inovio Pharmaceuticals (INO) experienced a monumental catalyst on October 30, 2026, when the U.S. FDA granted accelerated approval for VOCERYQ (INO-3107) for adult patients with recurrent respiratory papillomatosis (RRP), representing the first-ever FDA approval of a plasmid DNA medicine. This transformed the company into a commercial-stage biotech, sending the stock up over 213% on November 2, 2026, closing at $1.89 with an unprecedented volume spike to 579,968 shares (compared to typical volumes under 10,000 shares). While this provides major platform validation and near-term upward momentum, commercial launch expenses and an estimated cash runway extending only into late Q1 2027 mean that dilution risk remains elevated as the company scales commercial infrastructure ahead of Q1 2027 launch.
News behind the analysis
- INOVIO Announces FDA Accelerated Approval of VOCERYQ™The U.S. FDA granted accelerated approval for VOCERYQ to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP), marking the first FDA-approved plasmid DNA medicine.
- Inovio Stock Soars Following FDA Approval for Rare Respiratory Disease ImmunotherapyShares surged over 190% following the FDA accelerated approval of Voceryq as trading volume skyrocketed to multi-month highs.
- Inovio Pharmaceuticals Skyrockets as First Commercial Drug Clears FDAH.C. Wainwright upgraded INO from Neutral to Buy and doubled its price target to $5.00, citing platform validation and up to $450M in peak sales potential for Voceryq.
- INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026Inovio announced it will release its Q3 2026 financial and operating results after market close on November 10, 2026, accompanied by a conference call.
- Inovio Pharmaceuticals (INO) Shares Surge 224% After FDA Approves Voceryq for RRPDetailed breakdown highlighting the valuation expansion and commercial readiness timeline, with shipments expected within 60 days and full rollout in Q1 2027.